Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (July 2023)
15 slides from Revive Therapeutics's investor presentation, July 2023
Slide 1: A Specialty Life Sciences Company – Corporate Presentation
A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation July 2023 OTCQB: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: [email protected]
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS Bucillamine Specialty life sciences company Advancing Bucillamine for Developing Psilocybin (oral and focused on developing novel infectious diseases and rare patch) for mental health uses and delivery forms of disorders conditions drugs Psilocybin Robust patent portfolio Near-te
Slide 4: Strategy
STRATEGY Clinical development of Targeting Infectious Novel Uses, Targeting FDA Bucillamine and Diseases, Formulations, and Designations: Psilocybin Mental Health and Rare Delivery System Orphan, Fast track, Disorders (Ischemia- Breakthrough Reperfusion) Therapy © COPYRIGHT 2020. Revive Therapeutics
Slide 5: Patent Portfolio
PATENT PORTFOLIO Title USPTO No. Status Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 62/991,996 Non-Provisional patent filed Use of Bucillamine in the Treatment of Gout US9662305 Issued on May 30, 2017 US 8642088 Issued on February 4, 2014 Drug Delivery System US 95
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases, Rare Disorders, Mental Illness Stage of Product Indication Regulatory Status Development Bucillamine Infectious Diseases Determining next steps Completed Phase 3 (Oral Tablet) COVID-19 and international opps Rare Inflammatory Bucillamine IND filing for
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORTUNITY Bucillamine Phase 3 study for Bucillamine Revive’s clinical history Bucillamine scientific COVID-19 Safety Profile with Bucillamine rationale as an intervention for COVID-19 (see Appendix) • Potential treatment for clinical symptoms • Well-known safety profile and pres
Slide 8: Psychedelics Opportunity
PSYCHEDELICS OPPORTUNITY Acquired Psilocin Pharma Corp. • Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis • Worked with Xanthic Bio Pharma and Green Growth Brands • Developed water Soluble THC and CBD products (Beverages, effervescent tablets) Psilocybin and MDMA Microneed
Slide 9: Formulation & Delivery Technology
FORMULATION & DELIVERY TECHNOLOGY Delivering naturally extracted and synthetic psychedelics DELIVERY SYSTEM Combines Tannin (antibacterial, antifungal, antioxidant, wound healing) and Chitosan (blood-clotting and antimicrobial) composites Releases (rapid, controlled, sustained), improved bioavailabi
Slide 10: Strategic Partners
STRATEGIC PARTNERS Psilocybin Oral Thin Film Microneedle Patch MDMA Collaboration Delivery Collaboration Collaboration Psilocybin Biosynthesis R&D partnership Collaboration Psilocybin © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 10
Slide 11: Expected Milestones
EXPECTED MILESTONES 2H 2023 • Complete reformulation of • Phase 1/2 study for Psilocybin Bucillamine IV for future studies (Methamphetamine Use in ischemia-reperfusion Disorder) at University of Wisconsin • IND-enabling studies of Psilocybin Patch • Psilocybin oral thin film development • MDMA patch
Slide 12: Team
TEAM Management Clinical & Regulatory Board of Directors • Michael Frank • Dr. Kelly McKee, Jr., MD, MPH • Michael Frank Chairman and CEO Chief Scientific Officer, Consultant Chairman and CEO • Carmelo Marrelli • Dr. Arshi Kizilbash, M.D. • William Jackson Chief Financial Officer Medical Advisor, Co
Slide 13: Stock Information
STOCK INFORMATION Ticker 52-Week High/Low Market Cap R V V (CSE) | R V V T F (OTCQB) | 31R (Frankfurt) CAD $0.485 / $0.02 CAD ~ $12,500,000 Share Price Capital Structure CAD $0.035 (July 20, 2023) 356,237,674 common shares © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 13
Slide 14: Appendix – Bucillamine Scientific Rationale for COVID-19
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac
Slide 15: Appendix – Bucillamine Scientific Rationale for COVID-19 References
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
Revive Therapeutics — Investor Presentation (July 2023) on 6ix